Led by investigators at the University of Trento in Italy, the team received a five-year, £5 million ($6.4 million) award recently to advance its work.
The privately held Cambridge, UK-based company announced earlier this month that it had raised an additional £11 million to support the commercialization of its platform.
In support of the launch, researchers published a study demonstrating the test can help improve diagnosis of patients with unclear results from standard cytology methods.
